Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of progenitor cell and protein therapeutics for underserved medical conditions.
Stemedica Cell Technologies Announces Completion of Enrollment in Phase I/IIA Clinical Trial for Ischemic Stroke
Stemedica announced completion of enrollment into “A Phase I/IIa, Multi-Center, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects with Ischemic Stroke.”
FDA Grants IND Approval for Phase IIa Clinical Trial Using Stemedica’s ITMSC Therapy to Treat Alzheimer’s Disease
Planned to Launch in the Fourth Quarter 2015 in the United States as the First Alzheimer’s Clinical Trial Using Intravenous Administration of Ischemia-Tolerant Mesenchymal Stem Cells (itMSCs) SAN DIEGO and Epalinges, Switzerland — June 9, 2015 — Stemedica Cell...
Stemedica Obtains an Exclusive Worldwide License for Stem Cell Stabilization and Preservation Technologies
Commercial-scale Preservation of Therapeutically-active Stem Cell-derived Products For Worldwide Marketplace Opportunities SAN DIEGO—March 24, 2015—Stemedica Cell Technologies Inc., (Stemedica), announced today that Universal Stabilization Technologies (UST) has...